TY - CHAP M1 - Book, Section TI - The Acquired Immunodeficiency Syndrome–Related Cancers A1 - Rios, Adan A1 - Hagemeister, Fredrick B. A2 - Kantarjian, Hagop M. A2 - Wolff, Robert A. Y1 - 2016 N1 - T2 - The MD Anderson Manual of Medical Oncology, 3e AB - The relationship between malignancies and acquired immunodeficiency syndrome (AIDS) changed in 1996 when highly active antiretroviral therapy (HAART) was introduced in industrial nations. Thanks to the United Nations and other philanthropy programs, HAART has also been successfully introduced into a number of developing nations (1). Africa, the pandemic epicenter, is the exception, due to the epidemic magnitude on that continent and its significant political and social turmoil. Prior to 1996, epidemiologists noted specific malignancies afflicting patients with AIDS, with a risk proportional to host immune status. Before HAART, AIDS patients could be separated into two groups: patients with an opportunistic infection as their first manifestation of AIDS (60%) and those with a malignancy as its mode of presentation (40%) (2). SN - PB - McGraw-Hill Medical CY - New York, NY Y2 - 2024/03/28 UR - hemonc.mhmedical.com/content.aspx?aid=1126745542 ER -